Lawmaker Probes FDA Decision on Avandia

CNBC.com: "WASHINGTON - A U.S. Senator on Monday asked the Food and Drug Administration to confirm whether its drug safety experts came within one vote of recommending a withdrawal of GlaxoSmithKline's diabetes drug Avandia for safety reasons. Sen. Charles Grassley of Iowa said his staff learned that an internal panel of government safety experts voted 8-7 to keep the blockbuster pill Avandia on the market earlier this month. In a letter to FDA, Grassley questioned why the agency did not disclose the vote, which reportedly occured at a closed-door meeting Oct. 2."